Can a phone app help people with HIV beat fatty liver disease?
NCT ID NCT07456332
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether a mobile app-based nutritional program can help people living with HIV and fatty liver disease lose at least 5% of their body weight in 6 months. Participants are randomly assigned to use the app or receive standard lifestyle advice. The goal is to find a practical, low-cost way to improve liver health and overall well-being.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
digital nutritional program (mobile app)
What this could lead to
If successful, this could provide a simple, scalable tool to help people with HIV manage weight and reduce liver fat, improving overall health.
What could go wrong
This is a small, early-stage study with no blinding, and results depend on participants sticking with the app. Weight loss may be modest or not sustained long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, 08907, Spain